These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25261419)

  • 1. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials.
    Shiber S; Yahav D; Avni T; Leibovici L; Paul M
    J Antimicrob Chemother; 2015 Jan; 70(1):41-7. PubMed ID: 25261419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials.
    Chen M; Zhang M; Huang P; Lin Q; Sun C; Zeng H; Deng Y
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):111-120. PubMed ID: 29343141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.
    Paul M; Silbiger I; Grozinsky S; Soares-Weiser K; Leibovici L
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003344. PubMed ID: 16437452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
    Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
    J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.
    Paul M; Lador A; Grozinsky-Glasberg S; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003344. PubMed ID: 24395715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
    Muhammed M; Flokas ME; Detsis M; Alevizakos M; Mylonakis E
    Open Forum Infect Dis; 2017; 4(2):ofx099. PubMed ID: 28702469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
    Son SK; Lee NR; Ko JH; Choi JK; Moon SY; Joo EJ; Peck KR; Park DA
    J Antimicrob Chemother; 2018 Oct; 73(10):2631-2642. PubMed ID: 29800480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis.
    O'Donnell JN; Rhodes NJ; Lopez J; Jett R; Scheetz MH
    Int J Antimicrob Agents; 2018 Oct; 52(4):451-458. PubMed ID: 29665442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
    Paul M; Yahav D; Fraser A; Leibovici L
    J Antimicrob Chemother; 2006 Feb; 57(2):176-89. PubMed ID: 16344285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
    Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
    Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.
    Vardakas KZ; Voulgaris GL; Maliaros A; Samonis G; Falagas ME
    Lancet Infect Dis; 2018 Jan; 18(1):108-120. PubMed ID: 29102324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Beta-Lactam/Beta-Lactamase Plus Metronidazole vs Carbapenem for Complicated Intra-abdominal Infections: A Meta-analysis of Randomized Controlled Trials.
    Che H; Wang J; Wang R; Cai Y
    Open Forum Infect Dis; 2021 Jan; 8(1):ofaa591. PubMed ID: 33511229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials.
    Marcus R; Paul M; Elphick H; Leibovici L
    Int J Antimicrob Agents; 2011 Jun; 37(6):491-503. PubMed ID: 21292449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.
    Paul M; Benuri-Silbiger I; Soares-Weiser K; Leibovici L
    BMJ; 2004 Mar; 328(7441):668. PubMed ID: 14996699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
    Goldenberg JZ; Ma SS; Saxton JD; Martzen MR; Vandvik PO; Thorlund K; Guyatt GH; Johnston BC
    Cochrane Database Syst Rev; 2013 May; (5):CD006095. PubMed ID: 23728658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
    Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
    Svetitsky S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.
    Lodise TP; Yucel E; Obi EN; Watanabe AH; Nathanson BH
    J Antimicrob Chemother; 2024 Jan; 79(1):82-95. PubMed ID: 37962080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.